Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Inclusion Criteria

• •Adult female or male participants.
• •ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy.
• •Evaluable disease (measurable disease per RECIST 1.1 or bone-only disease).
• •De novo advanced breast cancer or with disease recurrence occurring after 12 months of completing adjuvant endocrine therapy (with or without CDK4/6 inhibitors)
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •Adequate hematologic, hepatic, and renal functions.
• •Female participants can be pre-, peri- or postmenopausal.
• •Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.